| Range: | 20.96-62.58 | Vol Avg: | 562785 | Last Div: | 0 | Changes: | 0.14 |
| Beta: | 0.75 | Cap: | 3.18B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Jul 24 2013 | Empoloyees: | 383 | ||
| CUSIP: | 00847X104 | CIK: | 0001439222 | ISIN: | US00847X1046 | Country: | US |
| CEO: | Mr. Brian M. Goff M.B.A. | Website: | https://www.agios.com | ||||
AGIO 55.68 Stock Price Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Stock Details
Neutral -0.10
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down
Agios' third-quarter 2024 earnings miss estimates while revenues match the same. Shares fa...
zacks.com·Fri Nov 01 2024
Positive 0.47
Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q3 2024 Earnings Conference Call October 31, 20...
seekingalpha.com·Thu Oct 31 2024
Neutral -0.01
Agios Reports Business Highlights and Third Quarter 2024 Financial Results
– Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; T...
globenewswire.com·Thu Oct 31 2024
Negative -0.20
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: A...
globenewswire.com·Thu Oct 17 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow